array(40) {
  [0]=>
  string(4) "8955"
  ["article_id"]=>
  string(4) "8955"
  [1]=>
  string(76) "Solvay announces partnership to protect healthcare workers on the front line"
  ["article_title"]=>
  string(76) "Solvay announces partnership to protect healthcare workers on the front line"
  [2]=>
  string(150) "Chemical company Solvay has partnered with aerospace company Boeing to produce protective equipment for healthcare professionals dealing with Covid-19"
  ["short_description"]=>
  string(150) "Chemical company Solvay has partnered with aerospace company Boeing to produce protective equipment for healthcare professionals dealing with Covid-19"
  [3]=>
  string(169) "Chemical company Solvay has partnered with aerospace company Boeing to produce protective equipment for healthcare professionals dealing with Covid-19 on the front line."
  ["description"]=>
  string(169) "Chemical company Solvay has partnered with aerospace company Boeing to produce protective equipment for healthcare professionals dealing with Covid-19 on the front line."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/solvay-announces-partnership-to-protect-healthcare-workers-o/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/solvay-announces-partnership-to-protect-healthcare-workers-o/"
  [15]=>
  string(19) "2020-04-02 22:28:30"
  ["add_date"]=>
  string(19) "2020-04-02 22:28:30"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8956"
  ["article_id"]=>
  string(4) "8956"
  [1]=>
  string(70) "Report claims medical plastics market will reach $37.5 billion by 2026"
  ["article_title"]=>
  string(70) "Report claims medical plastics market will reach $37.5 billion by 2026"
  [2]=>
  string(150) "A study published by Polaris Market Research claims that the global medical plastics market is predicted to reach over USD 37.5 billion by 2026, growi"
  ["short_description"]=>
  string(150) "A study published by Polaris Market Research claims that the global medical plastics market is predicted to reach over USD 37.5 billion by 2026, growi"
  [3]=>
  string(201) "A study published by Polaris Market Research claims that the global medical plastics market is predicted to reach over USD 37.5 billion by 2026, growing at a Compound Annual Growth Rate (CAGR) of 6.1%."
  ["description"]=>
  string(201) "A study published by Polaris Market Research claims that the global medical plastics market is predicted to reach over USD 37.5 billion by 2026, growing at a Compound Annual Growth Rate (CAGR) of 6.1%."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/report-claims-medical-plastics-market-will-reach-37-5-billio/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/report-claims-medical-plastics-market-will-reach-37-5-billio/"
  [15]=>
  string(19) "2020-04-02 21:50:00"
  ["add_date"]=>
  string(19) "2020-04-02 21:50:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8957"
  ["article_id"]=>
  string(4) "8957"
  [1]=>
  string(55) "Rapid diagnostic test for Covid-19 rolled out in the US"
  ["article_title"]=>
  string(55) "Rapid diagnostic test for Covid-19 rolled out in the US"
  [2]=>
  string(147) "A new point-of-care diagnostic test that can confirm exposure to Covid-19 in just 15 minutes is being rolled out to healthcare providers in the US."
  ["short_description"]=>
  string(147) "A new point-of-care diagnostic test that can confirm exposure to Covid-19 in just 15 minutes is being rolled out to healthcare providers in the US."
  [3]=>
  string(147) "A new point-of-care diagnostic test that can confirm exposure to Covid-19 in just 15 minutes is being rolled out to healthcare providers in the US."
  ["description"]=>
  string(147) "A new point-of-care diagnostic test that can confirm exposure to Covid-19 in just 15 minutes is being rolled out to healthcare providers in the US."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(110) "https://www.medicalplasticsnews.com/mpn-north-america/rapid-diagnostic-test-for-covid-19-rolled-out-in-the-us/"
  ["blog_url"]=>
  string(110) "https://www.medicalplasticsnews.com/mpn-north-america/rapid-diagnostic-test-for-covid-19-rolled-out-in-the-us/"
  [15]=>
  string(19) "2020-04-02 21:05:58"
  ["add_date"]=>
  string(19) "2020-04-02 21:05:58"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8867"
  ["article_id"]=>
  string(4) "8867"
  [1]=>
  string(71) "SI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic"
  ["article_title"]=>
  string(71) "SI-BONE, Inc. Provides Business Update in Response to COVID-19 Pandemic"
  [2]=>
  string(150) "SANTA CLARA, Calif., April  02, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal d"
  ["short_description"]=>
  string(150) "SANTA CLARA, Calif., April  02, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal d"
  [3]=>
  string(410) "
SANTA CLARA, Calif., April  02, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today provided an update on the actions it is taking to support patients, customers, and employees while maintaining business continuity in response to the coronavirus (COVID-19) pandemic.
"
  ["description"]=>
  string(410) "
SANTA CLARA, Calif., April  02, 2020  (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today provided an update on the actions it is taking to support patients, customers, and employees while maintaining business continuity in response to the coronavirus (COVID-19) pandemic.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(140) "http://www.globenewswire.com/news-release/2020/04/02/2010817/0/en/SI-BONE-Inc-Provides-Business-Update-in-Response-to-COVID-19-Pandemic.html"
  ["blog_url"]=>
  string(140) "http://www.globenewswire.com/news-release/2020/04/02/2010817/0/en/SI-BONE-Inc-Provides-Business-Update-in-Response-to-COVID-19-Pandemic.html"
  [15]=>
  string(19) "2020-04-02 21:00:00"
  ["add_date"]=>
  string(19) "2020-04-02 21:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8868"
  ["article_id"]=>
  string(4) "8868"
  [1]=>
  string(145) "Aesthetic Medical International Holdings Group Limited Enters into Definitive Agreements to Acquire Controlling Interest in Two Treatment Centers"
  ["article_title"]=>
  string(145) "Aesthetic Medical International Holdings Group Limited Enters into Definitive Agreements to Acquire Controlling Interest in Two Treatment Centers"
  [2]=>
  string(158) "Shenzhen, April  02, 2020  (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading pr"
  ["short_description"]=>
  string(158) "Shenzhen, April  02, 2020  (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading pr"
  [3]=>
  string(430) "
Shenzhen, April  02, 2020  (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announced the Company, through its affiliates, entered into definitive agreements (the “Agreements”) to acquire controlling interest in two treatment centers in March 2020.
"
  ["description"]=>
  string(430) "
Shenzhen, April  02, 2020  (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announced the Company, through its affiliates, entered into definitive agreements (the “Agreements”) to acquire controlling interest in two treatment centers in March 2020.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(216) "http://www.globenewswire.com/news-release/2020/04/02/2010760/0/en/Aesthetic-Medical-International-Holdings-Group-Limited-Enters-into-Definitive-Agreements-to-Acquire-Controlling-Interest-in-Two-Treatment-Centers.html"
  ["blog_url"]=>
  string(216) "http://www.globenewswire.com/news-release/2020/04/02/2010760/0/en/Aesthetic-Medical-International-Holdings-Group-Limited-Enters-into-Definitive-Agreements-to-Acquire-Controlling-Interest-in-Two-Treatment-Centers.html"
  [15]=>
  string(19) "2020-04-02 20:30:00"
  ["add_date"]=>
  string(19) "2020-04-02 20:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:04"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:04"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8855"
  ["article_id"]=>
  string(4) "8855"
  [1]=>
  string(54) "Galectin Therapeutics Update on the Impact of COVID-19"
  ["article_title"]=>
  string(54) "Galectin Therapeutics Update on the Impact of COVID-19"
  [2]=>
  string(150) "NORCROSS, Ga., April  02, 2020  (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target gale"
  ["short_description"]=>
  string(150) "NORCROSS, Ga., April  02, 2020  (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target gale"
  [3]=>
  string(312) "
NORCROSS, Ga., April  02, 2020  (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.
"
  ["description"]=>
  string(312) "
NORCROSS, Ga., April  02, 2020  (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(125) "http://www.globenewswire.com/news-release/2020/04/02/2010744/0/en/Galectin-Therapeutics-Update-on-the-Impact-of-COVID-19.html"
  ["blog_url"]=>
  string(125) "http://www.globenewswire.com/news-release/2020/04/02/2010744/0/en/Galectin-Therapeutics-Update-on-the-Impact-of-COVID-19.html"
  [15]=>
  string(19) "2020-04-02 20:03:00"
  ["add_date"]=>
  string(19) "2020-04-02 20:03:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:41:59"
  ["create_at"]=>
  string(19) "2020-04-12 16:41:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8958"
  ["article_id"]=>
  string(4) "8958"
  [1]=>
  string(64) "Industry bodies issue joint statement on testing for coronavirus"
  ["article_title"]=>
  string(64) "Industry bodies issue joint statement on testing for coronavirus"
  [2]=>
  string(150) "The British In Vitro Diganostic Association (BIVDA), Association of British HealthTech Industries (ABHI), Association of the British Pharmaceutical In"
  ["short_description"]=>
  string(150) "The British In Vitro Diganostic Association (BIVDA), Association of British HealthTech Industries (ABHI), Association of the British Pharmaceutical In"
  [3]=>
  string(237) "The British In Vitro Diganostic Association (BIVDA), Association of British HealthTech Industries (ABHI), Association of the British Pharmaceutical Industry (ABPI) and the UK BioIndustry Association (BIA) have released a joint statement."
  ["description"]=>
  string(237) "The British In Vitro Diganostic Association (BIVDA), Association of British HealthTech Industries (ABHI), Association of the British Pharmaceutical Industry (ABPI) and the UK BioIndustry Association (BIA) have released a joint statement."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/industry-bodies-issue-joint-statement-on-testing-for-coronav/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/industry-bodies-issue-joint-statement-on-testing-for-coronav/"
  [15]=>
  string(19) "2020-04-02 19:47:11"
  ["add_date"]=>
  string(19) "2020-04-02 19:47:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:21"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8817"
  ["article_id"]=>
  string(4) "8817"
  [1]=>
  string(106) "FDA Approves Emergency IND Use of Humanigen’s Lenzilumab for Compassionate Use in COVID-19 Patients"
  ["article_title"]=>
  string(106) "FDA Approves Emergency IND Use of Humanigen’s Lenzilumab for Compassionate Use in COVID-19 Patients"
  [2]=>
  string(150) "Burlingame, CA, April 2, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company foc"
  ["short_description"]=>
  string(150) "Burlingame, CA, April 2, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company foc"
  [3]=>
  string(248) "Burlingame, CA, April 2, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary..."
  ["description"]=>
  string(248) "Burlingame, CA, April 2, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(281) "https://www.drugs.com/clinical_trials/fda-approves-emergency-ind-humanigen-s-lenzilumab-compassionate-covid-19-patients-18517.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Emergency+IND+Use+of+Humanigen%E2%80%99s+Lenzilumab+for+Compassionate+Use+in+COVID-19+Patients"
  ["blog_url"]=>
  string(281) "https://www.drugs.com/clinical_trials/fda-approves-emergency-ind-humanigen-s-lenzilumab-compassionate-covid-19-patients-18517.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Emergency+IND+Use+of+Humanigen%E2%80%99s+Lenzilumab+for+Compassionate+Use+in+COVID-19+Patients"
  [15]=>
  string(19) "2020-04-02 13:04:18"
  ["add_date"]=>
  string(19) "2020-04-02 13:04:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8856"
  ["article_id"]=>
  string(4) "8856"
  [1]=>
  string(88) "Press Release Biocartis Group NV: Biocartis Announces Publication of 2019 Annual Report "
  ["article_title"]=>
  string(88) "Press Release Biocartis Group NV: Biocartis Announces Publication of 2019 Annual Report "
  [2]=>
  string(79) "PRESS RELEASE: REGULATED INFORMATION       2 April 2020, 07:00 CEST"
  ["short_description"]=>
  string(79) "PRESS RELEASE: REGULATED INFORMATION       2 April 2020, 07:00 CEST"
  [3]=>
  string(111) "
PRESS RELEASE: REGULATED INFORMATION       
2 April 2020, 07:00 CEST
"
  ["description"]=>
  string(111) "
PRESS RELEASE: REGULATED INFORMATION       
2 April 2020, 07:00 CEST
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(157) "http://www.globenewswire.com/news-release/2020/04/02/2010440/0/en/Press-Release-Biocartis-Group-NV-Biocartis-Announces-Publication-of-2019-Annual-Report.html"
  ["blog_url"]=>
  string(157) "http://www.globenewswire.com/news-release/2020/04/02/2010440/0/en/Press-Release-Biocartis-Group-NV-Biocartis-Announces-Publication-of-2019-Annual-Report.html"
  [15]=>
  string(19) "2020-04-02 13:00:00"
  ["add_date"]=>
  string(19) "2020-04-02 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:41:59"
  ["create_at"]=>
  string(19) "2020-04-12 16:41:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8857"
  ["article_id"]=>
  string(4) "8857"
  [1]=>
  string(85) "Persbericht Biocartis Group NV: Biocartis kondigt publicatie van 2019 jaarverslag aan"
  ["article_title"]=>
  string(85) "Persbericht Biocartis Group NV: Biocartis kondigt publicatie van 2019 jaarverslag aan"
  [2]=>
  string(64) "PERSBERICHT: GEREGLEMENTEERDE INFORMATIE2 april 2020, 07:00 CEST"
  ["short_description"]=>
  string(64) "PERSBERICHT: GEREGLEMENTEERDE INFORMATIE2 april 2020, 07:00 CEST"
  [3]=>
  string(96) "
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE
2 april 2020, 07:00 CEST
"
  ["description"]=>
  string(96) "
PERSBERICHT: GEREGLEMENTEERDE INFORMATIE
2 april 2020, 07:00 CEST
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(155) "http://www.globenewswire.com/news-release/2020/04/02/2010440/0/nl/Persbericht-Biocartis-Group-NV-Biocartis-kondigt-publicatie-van-2019-jaarverslag-aan.html"
  ["blog_url"]=>
  string(155) "http://www.globenewswire.com/news-release/2020/04/02/2010440/0/nl/Persbericht-Biocartis-Group-NV-Biocartis-kondigt-publicatie-van-2019-jaarverslag-aan.html"
  [15]=>
  string(19) "2020-04-02 13:00:00"
  ["add_date"]=>
  string(19) "2020-04-02 13:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:41:59"
  ["create_at"]=>
  string(19) "2020-04-12 16:41:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8818"
  ["article_id"]=>
  string(4) "8818"
  [1]=>
  string(160) "Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia"
  ["article_title"]=>
  string(160) "Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia"
  [2]=>
  string(158) "WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSE"
  ["short_description"]=>
  string(158) "WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSE"
  [3]=>
  string(252) "WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is..."
  ["description"]=>
  string(252) "WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/vanda-pharmaceuticals-announces-initiation-odyssey-fda-approved-clinical-study-tradipitant-18515.html?utm_source=ddc&utm_medium=rss&utm_campaign=Vanda+Pharmaceuticals+Announces+the+Initiation+of+ODYSSEY%2C+an+FDA+Approved+Clinical+Study+of+Tradipitant+in+Hospita"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/vanda-pharmaceuticals-announces-initiation-odyssey-fda-approved-clinical-study-tradipitant-18515.html?utm_source=ddc&utm_medium=rss&utm_campaign=Vanda+Pharmaceuticals+Announces+the+Initiation+of+ODYSSEY%2C+an+FDA+Approved+Clinical+Study+of+Tradipitant+in+Hospita"
  [15]=>
  string(19) "2020-04-02 12:04:40"
  ["add_date"]=>
  string(19) "2020-04-02 12:04:40"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8819"
  ["article_id"]=>
  string(4) "8819"
  [1]=>
  string(134) "Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients"
  ["article_title"]=>
  string(134) "Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients"
  [2]=>
  string(154) "VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  ["short_description"]=>
  string(154) "VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-sta"
  [3]=>
  string(255) "VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  ["description"]=>
  string(255) "VANCOUVER, Washington, April 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/cytodyn-s-leronlimab-indicates-significant-trend-toward-immunological-restoration-severely-ill-18512.html?utm_source=ddc&utm_medium=rss&utm_campaign=Treatment+with+CytoDyn%27s+Leronlimab+Indicates+Significant+Trend+Toward+Immunological+Restoration+in+Severely+Il"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/cytodyn-s-leronlimab-indicates-significant-trend-toward-immunological-restoration-severely-ill-18512.html?utm_source=ddc&utm_medium=rss&utm_campaign=Treatment+with+CytoDyn%27s+Leronlimab+Indicates+Significant+Trend+Toward+Immunological+Restoration+in+Severely+Il"
  [15]=>
  string(19) "2020-04-02 12:04:25"
  ["add_date"]=>
  string(19) "2020-04-02 12:04:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:45"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:45"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}